{"product_id":"sisram-medical-pestle-analysis","title":"Sisram Medical PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic advantage with our concise PESTLE Analysis of Sisram Medical—uncover how political shifts, regulatory risks, economic trends, and technological advances shape the company’s trajectory; purchase the full report for a comprehensive, actionable breakdown tailored for investors, consultants, and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical stability and Israel-China relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs an Israel-headquartered firm owned by Fosun Pharma, Sisram Medical faces geopolitical risk: Israel-China tensions and broader US-China trade frictions could disrupt its supply chains and cross-border tech flows; e.g., 2024 Israel exports to China fell 6.2% while Chinese FDI into Israel slowed 18% YoY, and investors should watch capital movement restrictions and potential tariff or export-control measures into late 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational trade policies and tariffs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChanges in US and EU import duties for medical devices—recent EU proposals targeting external tariffs and US Section 301 reviews—can shift Sisram Medicals gross margins; medical device tariff changes of even 2-5% would reduce margins on exported devices priced at $20k–$100k. \u003c\/p\u003e\n\u003cp\u003eRising trade protectionism and tariffs on energy-based aesthetic systems risk raising COGS for distributors by an estimated 3–7%, squeezing distributor margins and potentially reducing annual international revenue growth (2024~2025) in core markets. \u003c\/p\u003e\n\u003cp\u003eShifts in trade blocs and regulatory alignment between the EU, UK, and US require Sisram to adjust supply chains and pricing to retain competitive positioning across markets where unit volume is sensitive to 5–10% price changes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare spending and subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment healthcare spending and subsidies indirectly shape demand for Sisram Medical: countries boosting medical tourism (e.g., UAE: health tourism receipts rose to $2.2bn in 2023) and offering tax credits for high-tech clinic investments can expand device uptake; conversely, reallocation of public budgets to pandemic response or primary care—WHO reports many LMICs cut elective services spending by up to 15% in 2020–24—can depress private aesthetic market growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory harmonization across borders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical efforts through WHO, IMDRF and EU-US dialogues to harmonize device standards accelerate Sisram Medical’s global launches; IMDRF members cover 60+ jurisdictions, potentially reducing duplicate testing and cutting time-to-market by up to 20% per industry estimates in 2024.\u003c\/p\u003e\n\u003cp\u003eShifts in EU MDR updates or FDA device reclassification in North America can lengthen approval cycles—EU conformity assessments rose 35% post‑MDR (2021–24), impacting timelines and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eMaintaining dedicated diplomatic and regulatory compliance teams is essential; Sisram’s regulatory spend benchmarked at ~2–4% of revenue in medtech helps manage multi-jurisdictional requirements and mitigate approval delays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIMDRF\/EU-US harmonization could cut time-to-market ~20%\u003c\/li\u003e\n\u003cli\u003eEU conformity assessments +35% (2021–24), slowing approvals\u003c\/li\u003e\n\u003cli\u003eRegulatory spend ~2–4% of revenue is industry benchmark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStability in emerging market jurisdictions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpsisram expansion into latin america and southeast asia is contingent on local political stability rule of law saw gdp volatility in several markets asean fx swings averaged affecting repatriation margins.\u003e\n\u003cppolitical volatility can trigger sudden licensing changes or currency devaluations and argentina remain high-risk while vietnam the philippines showed improving governance scores in\u003e\n\u003cpstrategic planning requires country-level political risk assessments scenario stress-tests and contingency capital reserves to protect long-term investments preserve projected roi.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrioritize markets with stable governance and ≤5% FX volatility\u003c\/li\u003e\n\u003cli\u003eMaintain 6–12 months operating reserves for high-risk jurisdictions\u003c\/li\u003e\n\u003cli\u003eUse political risk insurance for exposures \u0026gt;$10M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pstrategic\u003e\u003c\/ppolitical\u003e\u003c\/psisram\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical shocks squeeze margins, trade \u0026amp; regs—hold 6–12 months reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions (Israel‑China, US‑China) and trade measures threaten supply chains and margins; 2024: Israel→China exports -6.2%, Chinese FDI into Israel -18% YoY. Tariff shifts of 2–5% cut margins on $20k–$100k devices; EU conformity assessments +35% (2021–24) lengthen approvals; regulatory spend ~2–4% revenue; recommend 6–12 months reserves for high‑risk markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/24–25 Impact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael→China exports\u003c\/td\u003e\n\u003ctd\u003e-6.2% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChinese FDI into Israel\u003c\/td\u003e\n\u003ctd\u003e-18% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU conformity assessments\u003c\/td\u003e\n\u003ctd\u003e+35% (2021–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff sensitivity\u003c\/td\u003e\n\u003ctd\u003e2–5%→margin pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e2–4% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReserve recommendation\u003c\/td\u003e\n\u003ctd\u003e6–12 months ops\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Sisram Medical across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—grounded in current market, regulatory, and industry trends to identify threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarized PESTLE insights for Sisram Medical presented in clear, stakeholder-friendly language to streamline meeting prep and support rapid alignment on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal discretionary spending trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand for aesthetic procedures like skin rejuvenation and body contouring is closely tied to disposable income among middle and upper classes; global cosmetic procedure spending reached about $75 billion in 2024, with non-surgical treatments up 6% year-on-year. By late 2025 cooling inflation (global CPI easing toward 3–4% in many markets) and stabilized rates supported rebounding consumer confidence. Localized downturns, however, can prompt postponements of non-essential treatments, directly reducing Sisram’s device and consumable sales volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSisram Medical reports in USD but operates globally, exposing reported revenue to fluctuations in the Israeli shekel, Chinese yuan and euro; for example, a 10% depreciation of the CNY vs USD in 2024 would reduce China-derived USD revenues materially given China accounted for over 25% of group sales in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and capital expenditure for clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMost of Sisram’s clients—medical clinics and aesthetic centers—rely on financing to buy laser and ultrasound systems; with global commercial loan rates averaging ~7.5% in 2024 and clinic loan spreads near 400 bps, borrowing costs rose materially. High rates in 2023–24 likely delayed replacement cycles, shrinking elective procedure capex; HISMarkit reported medical device purchases fell ~8% YoY in 2024. As central banks signal easing into 2026 and equipment financing rates are forecasted to drop toward 5–6%, Sisram could see a pickup in upgrade orders. Lower rates would shorten payback periods, improving ROI calculations for clinics and supporting stronger equipment demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the medical aesthetics market in APAC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe APAC medical aesthetics market was valued at about USD 14.6 billion in 2024 and is projected to grow at ~11% CAGR to 2030, driven by China and India where rising high-net-worth individuals and urbanization boost demand for premium procedures.\u003c\/p\u003e\n\u003cp\u003eEconomic liberalization, expanding middle classes, and increased healthcare spending underpin sustainable uptake of advanced devices and consumables; Sisram, via Alajlan Group\/Sunrise ties and strong Chinese market access, is well positioned to capture share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAPAC market ~USD 14.6B (2024), ~11% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eChina and India = primary demand drivers; rapidly growing affluent populations\u003c\/li\u003e\n\u003cli\u003eRising urbanization and healthcare spend support premium device adoption\u003c\/li\u003e\n\u003cli\u003eSisram benefits from parent company’s deep Chinese market roots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor costs and manufacturing efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRising wages in key manufacturing hubs—China up ~5.5% y\/y in 2024 and Vietnam wages up ~8% since 2022—raise production costs for Sisram’s energy-based devices and digital platforms, squeezing margins if unaddressed.\u003c\/p\u003e\n\u003cp\u003eTo protect profitability Sisram needs capital investment in automation and supply-chain optimization; automation can cut unit labor costs by 20–30% per industry estimates, while optimized sourcing reduces COGS volatility.\u003c\/p\u003e\n\u003cp\u003eEconomic feasibility hinges on balancing high-quality engineering with scalable, cost-effective production as Sisram expands its global footprint and targets mid-single-digit EBITDA margin improvement by 2025–2026.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWage inflation: China ~5.5% (2024), Vietnam ~8% (2022–24)\u003c\/li\u003e\n\u003cli\u003eAutomation potential: −20–30% unit labor cost\u003c\/li\u003e\n\u003cli\u003eTarget: mid-single-digit EBITDA uplift by 2025–26 through efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPAC aesthetics: $14.6B market, China \u0026gt;25% amid wage pressure—automation boosts EBITDA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic tailwinds: global aesthetic spend ~$75B (2024), APAC ~$14.6B (2024) with ~11% CAGR to 2030; China \u0026gt;25% group sales (2023–24). Headwinds: higher borrowing (~7.5% avg 2024) and wage inflation (China ~5.5% 2024, Vietnam ~8% 2022–24) press capex and margins; automation could cut labor costs 20–30%, supporting mid-single-digit EBITDA uplift by 2025–26.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal aesthetic spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$75B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC (2024)\u003c\/td\u003e\n\u003ctd\u003e$14.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina share\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg loan rate (2024)\u003c\/td\u003e\n\u003ctd\u003e~7.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina wage growth (2024)\u003c\/td\u003e\n\u003ctd\u003e~5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eSisram Medical PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Sisram Medical PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic planning or investment review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752102506873,"sku":"sisram-medical-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/sisram-medical-pestle-analysis.png?v=1772237615","url":"https:\/\/matrixbcg.com\/products\/sisram-medical-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}